DC Circ. Won't Revive FTC's Endo-Impax Deal Suit
By Bryan Koenig · August 25, 2023, 8:13 PM EDT
A D.C. Circuit panel refused Friday to revive a Federal Trade Commission lawsuit targeting an opioid medication settlement between Endo Pharmaceuticals and Impax, concluding the license brandmaker Endo granted for Impax...
To view the full article, register now.